Tobias Welte
Hannover Medical School
1134 Papers
5.5K Citations
Tobias Welte is an academic researcher from Hannover Medical School. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 93, co-authored 976 publications. Previous affiliations of Tobias Welte include Hochschule Hannover.
Chat about Author
Papers
Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma
Marc A. Schneider,Sarah Richtmann,A. Gründing,Sabine Wrenger,Tobias Welte,Michael Meister,Mark Kriegsmann,Hauke Winter,Thomas Muley,Sabina Janciauskiene +9 more
TL;DR: It is found that lower TMPRSS2 expression in tumor compared to adjacent non-tumor tissues is linked to a poor overall survival in patients with adenocarcinoma (ADC) and those who are current smokers.
Plasma Acute Phase Proteins as Predictors of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients.
Sabina Janciauskiene,Pierre-Joseph Royer,Jan Fuge,Sabine Wrenger,Joanna Chorostowska-Wynimko,Christine S. Falk,Tobias Welte,Martine Reynaud-Gaubert,Antoine Roux,Adrien Tissot,Antoine Magnan +10 more
TL;DR: The findings suggest that profiles of certain APPs may help to predict the development of lung dysfunction at the very early stages after transplantation.
Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
Nora Drick,Katrin Milger,Benjamin Seeliger,Jan Fuge,Stephanie Korn,Roland Buhl,Maren Schuhmann,Felix J.F. Herth,Benjamin Kendziora,Juergen Behr,Nikolaus Kneidinger,Karl-Christian Bergmann,Christian Taube,Tobias Welte,Hendrik Suhling +14 more
TL;DR: Switching from anti- IL-5 to anti-IL-5Rα therapy in patients with inadequate response was associated with significantly improved FEV1, asthma control and OCS reduction.
Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma
TL;DR: This study of the eosinophil cationic protein (ECP) as predictor of clinical response to biological therapy in severe asthma found that ECP is not useful in unselected patients but may have a role in those not exposed to oral corticosteroids.
Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation.
Fabio Ius,Wiebke Sommer,Igor Tudorache,Christian Kühn,Murat Avsar,Thierry Siemeni,Jawad Salman,Michael Hallensleben,Daniela Kieneke,Mark Greer,Jens Gottlieb,Jan T. Kielstein,Dietmar Boethig,Tobias Welte,Axel Haverich,Gregor Warnecke +15 more
TL;DR: Preemptive treatment with therapeutic plasma exchange and rituximab led to improved elimination of de novo donor-specific anti-human leukocyte antigen antibodies early after lung transplantation, but spontaneous elimination in untreated Group B patients also occurred frequently.